WindRose Health Investors has closed its seventh private equity fund at $2.6 billion, marking the largest fundraise in the firm’s history and nearly doubling the size of its prior vehicle. The New York-based healthcare investor reached its hard cap after a six-month fundraising period, attracting a global base of limited partners from pensions, insurers, financial institutions, foundations, funds of funds, and family offices.
The firm plans to complete its first two acquisitions under the new fund by the end of 2025 and is targeting 11 to 13 total investments. WindRose invests in healthcare services companies nationwide, focusing on businesses with strong profitability and cost-efficient operating models. With approximately $7 billion under management, the firm emphasized that Fund VII will continue its strategy of backing tech-enabled platforms that improve quality and streamline efficiency across the healthcare ecosystem.
The firm noted that strong LP demand came during a challenging period for private equity fundraising, highlighting continued appetite for healthcare services and next-generation operating models. Evercore Private Funds Group served as the exclusive global placement agent for the fund, while Kirkland & Ellis provided legal counsel.
KEY QUOTES
“We are deeply grateful for the ongoing support of our existing investors as well as the confidence placed in us by a world-class group of new investors across the Americas, Europe, the Middle East and Asia. As a result of their trust, we were able to close Fund VII in just six months. We are now eager to get to work on our latest fund and are optimistic about continued opportunities to invest in innovative, tech-enabled businesses that are improving quality and enhancing efficiency in healthcare.”
Oliver T. Moses, Managing Partner, WindRose
“We appreciate our investors’ continued confidence, especially in a challenging fundraising environment. WindRose believes that it has developed a set of value creation capabilities that is built for the direction of the healthcare industry and gives our portfolio companies a significant competitive advantage in the race to innovate and grow.”
Catherine Coleman, Head of Investor Relations, WindRose
